Debt - Liability for Sale of Future Royalties (Details) $ in Thousands |
9 Months Ended |
|---|---|
|
Sep. 30, 2026
USD ($)
| |
| Debt | |
| Beginning balance | $ 2,308,366 |
| Less: Non-cash royalty revenue payable to Royalty Pharma | (199,624) |
| Plus: non-cash interest expense recognized | 196,861 |
| Ending balance | $ 2,305,603 |
| Effective interest rate of the liability component | 11.00% |
| X | ||||||||||
- Definition Amount of liabilities related to the sale of future royalties. No definition available.
|
| X | ||||||||||
- Definition Amount of interest expense recognized related to the liability for the sale of future royalties per terms of the agreement. No definition available.
|
| X | ||||||||||
- Definition Amount of royalty revenue recognized during the period relating to the sale of future royalties payable under terms of the agreement. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|